Mergers and acquisitions

Flu virus
#Antivirals #Biologics / Biotechnology #Cidara #Influenza #Merck #Mergers and acquisitions

Merck acquires antivirals developer Cidara Therapeutics

Merck (MSD outside of the US and Canada) has acquired Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for approximately $9.2 billion.  Cidara’s lead candidate, CD388, consists of a small molecule neuraminidase inhibitor stably conjugated to a proprietary Fc fragment of a human antibody designed… Read More

#Business & Investment #News

Avidity Biosciences HQ
#Antibodies #Avidity Biosciences #Bioconjugates #Mergers and acquisitions #Novartis #Oligonucleotides

Novartis acquires Avidity Biosciences for $12 billion

Novartis has entered into a definitive merger agreement with antibody oligonucleotide conjugates (AOCs) developer Avidity Biosciences.   The acquisition will follow the separation of Avidity’s early-stage precision cardiology programmes into SpinCo, which is expected to be a publicly traded company.   SpinCo will be led by Kathleen… Read More

#Business & Investment #News

Metsera logo
#Mergers and acquisitions #Metsera #Novo Nordisk #Obesity #Pfizer #Weight loss

Pfizer finally wins bidding war to acquire Metsera

Following a week-long bidding war with Novo Nordisk, Pfizer has acquired obesity drug specialists Metsera for $10 billion, thanks to an intervention by the US Federal Trade Commission (FTC).  Metsera’s Board of Directors unanimously recommended that Metsera stockholders approve the adoption of the amended Pfizer merger agreement… Read More

#Business & Investment #News #Trending News

CAR T-cells attacking a cancer cell
#Bristol Myers Squibb #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

BMS boosts cell therapy portfolio with Orbital acquisition

Bristol Myers Squibb has announced plans to acquire in vivo CAR-T company Orbital Therapeutics for $1.5 billion.  The acquisition includes Orbital’s lead RNA immunotherapy preclinical candidate currently in IND-enabling studies, OTX-201, which comprises an optimised circular RNA encoding a CD19-targeted CAR for in vivo… Read More

#Business & Investment #News

Novo Nordisk head office
#Liver disease #Mergers and acquisitions #Metabolic diseases #Novo Nordisk

Akero Therapeutics acquired by Novo Nordisk for $5.2B

Akero Therapeutics, a clinical-stage company focused on serious metabolic diseases, has entered into a definitive agreement to be acquired by Novo Nordisk for up to $5.2 billion in cash. The acquisition was announced as Novo Nordisk revealed it is closing its cell therapy division, with a loss of 250… Read More

#Business & Investment #News

#Autoimmune disease #Diabetes #Mergers and acquisitions #Metabolic diseases

Barinthus Bio and Clywedog Therapeutics announce merger

Immunology and inflammation company Barinthus Biotherapeutics and private company Clywedog Therapeutics will merge to target metabolic and autoimmune diseases, the companies have announced.  The combined company, named Clywedog Therapeutics, will now advance a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases. The portfolio includes three… Read More

#Business & Investment #News

Bispecific antibodies
#Bispecific Antibodies #Genmab #Head and neck cancer #Mergers and acquisitions #Oncology

Genmab to acquire Merus for approximately $8 billion

Genmab has agreed to acquire Merus, a clinical-stage biotechnology company with a late-stage breakthrough therapy asset called petosemtamab, which is in Phase III development.  Genmab will pay $97.00 per share in an all-cash transaction representing a transaction value of approximately $8 billion.   The proposed acquisition… Read More

#Business & Investment #News

Close up of vaccine syringe
#Immunology / Virology & Vaccines #Mergers and acquisitions #Respiratory #Sanofi #Vaccines #Vicebio

Harnessing molecular clamp technology for respiratory vaccines

Sanofi explores the acquisition of Vicebio and its Molecular Clamp technology, highlighting how it strengthens the company’s respiratory vaccine portfolio with next-generation combination candidates. Q: Sanofi has described the acquisition of Vicebio as a step toward next-generation combination vaccines. What gaps or opportunities does this address in your… Read More

#Exclusive Content

#AbbVie #Major depressive disorder #Mergers and acquisitions #Psychedelics #Psychiatry

AbbVie acquires psychedelic for major depressive disorder

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead asset, bretisilocin (GM-2505), a potential best-in-class compound for the treatment of major depressive disorder (MDD), for up to $1.2 billion.  Psychedelic compounds have gained recognition as potential treatments for mental health disorders, because of their demonstrated rapid, robust and… Read More

#Business & Investment #News

#Collaboration #Drug discovery #Mergers and acquisitions #Partnership

New DDW Highlights podcast: 26 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The news this week has emphasised the importance of shared knowledge and expertise to the… Read More

#News

#Collaboration #Drug discovery #Mergers and acquisitions #Partnership

This week in drug discovery (18-22 August) 

News round-up for 18-22 August by DDW Senior Digital Content Editor Diana Turner. The news this week has emphasised the importance of shared knowledge and expertise to the development of new drugs, whether that is through research collaboration agreements or mergers and acquisitions, with a number of new… Read More

#News

CAR-T cell attacking cancer
#CAR-T #Cell therapy #In vivo #Kite Pharma #Mergers and acquisitions

Kite acquires in vivo CAR-T developer for $350 million

Gilead-owned Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million.  The acquisition complements Kite’s focus on cell therapy by incorporating Interius’s integrating in vivo platform.   This… Read More

#Business & Investment #News

Human cell
#10x Genomics #Drug discovery #Mergers and acquisitions #Scale Biosciences #Single-cell analysis

10x Genomics expands single cell analysis with Scale buyout

10x Genomics has acquired Scale Biosciences, gaining key inventions and technologies and broadening access to single cell analysis.  Scale Biosciences was founded by a multidisciplinary team of scientists and technologists with expertise in next generation sequencing, genomics, and bioinformatics: Professor Garry Nolan at Stanford University, Professors Jay… Read More

#Business & Investment #News

Human brain
#Mergers and acquisitions #Neurodegenerative disorders #Neuroscience #Sanofi #Vigil Neuroscience

Sanofi completes acquisition of Vigil Neuroscience

Sanofi has completed its acquisition of Vigil Neuroscience, adding VG-3927, a novel, oral, small-molecule TREM2 agonist, to Sanofi’s neurology pipeline.  Vigil is a clinical-stage biotechnology company targeting neurodegenerative diseases through disease-modifying therapeutics that restore the vigilance of microglia.  Sanofi will also acquire Vigil’s preclinical pipeline… Read More

#Business & Investment #News

#Automation #Drug discovery #Lab technology #Labguru #Mergers and acquisitions #Titian

Labguru and Titian Software Rebrand as Cenevo

Titian Software and Labguru have rebranded as Cenevo, bringing together the two companies’ solutions, Labguru and Mosaic, under a new, unified brand.   The combined organisation specialises in lab management systems, automation, orchestration, data management and AI technology.  The new company says that Cenevo software will… Read More

#Business & Investment #News

#Adaptimmune Therapeutics #Cell therapy #Mergers and acquisitions

Adaptimmune sells cell therapies to US WorldMeds

Adaptimmune Therapeutics has entered into a definitive agreement for the sale of Tecelra, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMeds.   The purchase price is $55 million in cash to be paid upon consummation of the sale, with up to $30 million in potential future payments… Read More

#Business & Investment #News